Best Genomics Companies in Seoul, South Korea
The 56 best Genomics companies in Seoul, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Wellmarker Bio.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Seoul
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 84 mo ago | Series B | Dong Hoon Co-Founder & Co-CEO | 2016 | — | 85 patents Targeted antibody therapeutics and biomarkers for cancer and kinase inhibitor response | — |
| 2 | Lemonex Developer of drug delivery technology and biosensor technology | $27M | 62 mo ago | Series C | Dal-Hee Min Co-Founder & CTO | 2013 | — | 181 patents Nanocarrier-based drug and nucleic‑acid delivery systems for antiviral and cancer therapies | — |
| 3 | 3billion Provider of AI-driven clinical diagnostic testing platform for rare genetics disease 74Product top 19%Tech top 22%AI top 25%Patents top 26% All 12 signals ▾Producttop 19% Techtop 22% AItop 25% Patentstop 26% Talenttop 28% Innovationtop 32% Moattop 32% Fundingtop 34% Growthtop 35% Marketbottom 49% Globalbottom 43% Fin. healthbottom 36% Product: 3 distinct product lines · Company stage: Public Tech: 49 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 rank vs industry peers · Fliar Intelligence Index 74/100 | $26M | 2 mo ago | Public | — | 2016 | TurbopackSentryApple iCloud Mail+21 | 59 patents AI-powered genomic variant analysis and clinical symptom similarity for precision medicine | 1 partnership |
| 4 | Deargen Developer of AI-based drug discovery platform for rare and intractable diseases | $17M | 52 mo ago | Series B | Gilsu Kang CEO | 2016 | — | 72 patents AI-driven small‑molecule design and target interaction prediction for drug discovery | — |
| 5 | Geninus Developer of genomic-based disease prevention platform | $13M | 71 mo ago | Public | — | 2018 | — | 39 patents Molecular diagnostics and immuno‑oncology biomarkers for cancer detection and therapy prediction | — |
| 6 | NGeneBio In vitro cancer diagnostic products | $13M | 91 mo ago | Public | Min-Sik Kim Co-CEO | 2015 | Microsoft ASP.NETGSAPCloudflare+8 | 46 patents Genetic diagnostics and personalized therapeutics via nucleic‑acid amplification and microbiome analysis | — |
| 7 | Genacast Provider of liquid-biopsy-based cancer detection platform | $12M | 73 mo ago | Series B | Seung Chan Baek CEO | 2016 | — | — | — |
| 8 | Abion Therapeutics for cancer and auto-immune diseases. | $11M | 131 mo ago | Public | — | 2007 | WordPressMySQLPHP+16 | 229 patents Kinase inhibitor small molecules and interferon‑beta biologics for cancer and antiviral therapies | — |
| 9 | AIGEN Sciences AI-based drug discovery and designing tool for researchers 35AI top 30%Moat top 38%Funding top 42%Patents top 46% All 8 signals ▾AItop 30% Moattop 38% Fundingtop 42% Patentstop 46% Innovationtop 48% Talentbottom 49% Globalbottom 31% Marketbottom 25% AI: Classified as an AI company · Product described with: ai-based Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $9M | 12 mo ago | Series A | Jaewoo Kang CEO | 2021 | — | 7 patents Patents concentrated in chemistry & materials | — |
| 10 | NewLacel Genetics Developer of adeno-associated virus gene therapy to treat neurodegenerative diseases | $9M | 92 mo ago | Series A | — | 2018 | — | — | — |
| 11 | ENCell Provider of services for stem cell research for drug development | $8M | 75 mo ago | Series A | Jang wook CEO | 2018 | Microsoft ASP.NETCloudflarejsDelivr+8 | 70 patents Patents concentrated in chemistry & materials | — |
| 12 | Novomics Developer of a molecular diagnosis system for cancer treatment | $3M | 115 mo ago | Series A | Huh Yongmin CEO | 2010 | — | 36 patents AI-based gastric cancer imaging analysis and predictive biomarkers for therapy response | — |
| 13 | Seegene Technologies Developer of molecular diagnostic kits to detect infectious and genetic diseases | $2M | 79 mo ago | Public | Jong Yoon Chun CEO | 2000 | Node.jsSalesforceTailwind CSS+14 | 1,257 patents Multiplex nucleic‑acid diagnostic assay design, automation, and data‑driven infectious disease testing | 1 launch · 1 award |
Top 12 Genomics companies in Seoul
#1
Public · Seoul, Seoul · founded 2016 · 75 employees$25.7Mraised▾
Provider of AI-driven clinical diagnostic testing platform for rare genetics disease. It uses a combination of next-generation sequencing, and advanced machine learning and deep learning algorithms to analyze whole patient genomes for disease-causing mutations. The company is developing a single test that can detect more than 4000 rare genetic disorders.
- Apr 2026Series D$20.3M
- Mar 2021Series C$13M
- Oct 2019Series B$10M
- Jul 2018Series A$2.7M
#2
Series A · Seoul, Seoul · founded 2021 · 8 employees$8.8Mraised▾
AI-based drug discovery and designing tool for researchers. The company has developed a proprietary tool AIGEN Discovery that assists with the discovery and designing of new drugs. The system can be used for drug targeting, data analysis, novel compounds optimization, and more.
- Jul 2025Series A—
- Oct 2024Series A$8.8M
#3
Series B · Seoul, Seoul · founded 2016 · 58 employees$45.2Mraised▾
Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG).
- Jul 2019Series B$16M
- Nov 2018Series A$25M
- Apr 2018Seed$4.2M
#4
Series C · Seoul, Seoul · founded 2013 · 9 employees$27.5Mraised▾
Developer of drug delivery technology and biosensor technology. The DegradaBALLis a drug delivery technology for the development of gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. The PANGO technology is the next-generation drug screening technology that allows the rapid screening of antiviral drugs from the drug candidate library.
- Apr 2021Series C$13.9M
- Dec 2018Series B$10.3M
- Mar 2018Series A$3.3M
#5
Series B · Seoul, Seoul · founded 2016 · 39 employees$17Mraised▾
Developer of AI-based drug discovery platform for rare and intractable diseases. The company's platform comprises genome data analysis, biomarker prediction, molecule selection, and optimization. It is used for discovering new disease targets for developing small molecule precision medicine.
- Feb 2022Series B$17M
#6
Public · Seoul, Seoul · founded 2018 · 94 employees$13.3Mraised▾
Geninus is a developer of a genomic-based disease prevention platform. It has developed a CancerScan test that detects mutations by deep sequencing based on NGS of tumor DNA extracted from cancer tissue . It supports in mutation detection and related target anticancer drugs with clinical utility through genomic analysis of cancer tissues. It also offers diet service through microbial community analysis by using genetic analysis technology. It provides single cell analysis service that analyzes single cells in the cancer genome. It helps to analyze the characteristics of individual cells and their distribution, type, and condition by cell type. It also offers services like LiquidSCAN, HealthSCAN, cancer genome analysis, microbial community genome, and many more.
- Aug 2020Series B$13.3M
- Dec 2018Series A—
- Oct 2018Angel—
#7
Series B · Seoul, Seoul · founded 2016 · 27 employees$11.6Mraised▾
“The earlier you discover, the better you recover†GENECAST is biotechnology company specialized in cancer diagnosis using liquid biopsy. ADPS, our proprietary technology which has maximum detection sensitivity of 0.0001%, can recognize cancer mutation genes quickly and accurately among other conventional liquid biopsy technologies. FACE CANCER with ADPS
#8
Public · Seoul, Seoul · founded 2015 · 124 employees$12.9Mraised▾
NGeneBio is offering products for in vitro diagnostic of oncology. It offers breast cancer detection kit, NSC for solid tumor detection, hematological malignancy panel, along with bioinformatics analysis software, and a genetic test for the short tandem repeat. The product portfolio of the company includes next-generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW) for applications in molecular diagnostics (MDx) and companion diagnostics (CDx). It can detect the mutation in BRCA genes.
- Dec 2018Series B$11M
- 2017Seed$1.9M
#9
Public · Seoul, Seoul · founded 2007 · 33 employees$10.8Mraised▾
Abion develops therapeutics for cancer and auto-immune diseases. Its pipeline has four candidates currently: a protein therapeutic for multiple sclerosis, two siRNA candidates for cervical cancer, and a small molecule therapeutic for lung cancer. All candidates are in pre-clinical testing.
- Aug 2015Grant (prize money)—
- Jul 2015Series A—
- Nov 2014Series A$1.9M
- Dec 2013Series A$5.7M
#10
Series A · Seoul, Seoul · founded 2018 · 104 employees$8Mraised▾
Provider of services for stem cell research for drug development. The company is developing next-generation cell/gene therapy and targeted gene therapy for incurable and incurable diseases. Also, offers CMO and CDMO services for drug development.
- Mar 2020Series A$8M
- Seed—
#11
Series A · Seoul, Seoul · founded 2018$8.8Mraised▾
Developer of adeno-associated virus gene therapy to treat neurodegenerative diseases
#12
Series A · Seoul, Seoul · founded 2010 · 5 employees$3.4Mraised▾
Developer of a molecular diagnosis system for cancer treatment. The company's flagship product, nProfiler -1 stomach cancer assay is a software-based molecular diagnostic assay that can predict the prognosis after stomach cancer surgery in patients with advanced gastric cancer 2 and 3. The assay kit measures the expression levels of 9 genes by RT and qPCR and then the prognosis can be done based on nDx 1 (Novomics diagnostic system 1), which is an algorithm-based software. Also developing lung cancer companion kit & Colorectal cancer IVDs based on the same system.
- Dec 2016Series A$3.4M
- 2015Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Seoul is moving
A read on the academic research around Bioinformatics in Seoul — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 188 papers.
Seoul National University and its hospitals dominate Seoul's bioinformatics research, focusing heavily on genomics, protein dynamics, and ML-driven transcriptomics, with a cautiously optimistic tone skewed toward breakthroughs over concerns.
- Seoul National University134
- Seoul National University Hospital37
- Seoul National University Bundang Hospital13
- The Catholic University of Korea Seoul St. Mary\'s Hospital8
- Hanyang University Seoul Hospital7
- Gene1→7
- Protein structure prediction1→3
- Genome4→5
- Microbiome6
- Disease6
- Immune system5
- Gene4
- Pathogenesis3
- Table (database)12
- Transcriptome12
- Sample (material)12
- Clinical trial3
- Immunotherapy3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.